Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,181 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02057640 | MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Jason ValentOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT01503242 | 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 | 15 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00861510 | A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies | completed | Phase 1 | 16 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02391480 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | completed | Phase 1 | 128 | AbbVieINDUSTRY | 1 | Nov 29, 2019 | clinicaltrials |
| NCT02254772 | A Phase I/II Study of Intratumoral Injection of SD-101 | completed | Phase 1 / Phase 2 | 9 | Robert LowskyOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02189343 | Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | completed | Phase 1 | 16 | CelgeneINDUSTRY | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00652626 | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function(RENAL) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00555100 | Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma | completed | Phase 1 | 15 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01568294 | Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma | completed | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01937442 | Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma | completed | Phase 1 | 7 | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT00005792 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma | completed | Phase 1 | 131 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01351935 | Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | completed | Phase 1 | 113 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00834665 | Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma | completed | Phase 1 | 59 | University of PennsylvaniaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT01142232 | Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma | completed | Phase 1 / Phase 2 | 60 | Attaya SuvannasankhaOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT01076543 | Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2019 | clinicaltrials |
| NCT02215967 | Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2019 | clinicaltrials |
| NCT00932698 | Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01001442 | Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 30, 2019 | clinicaltrials |
| NCT02950220 | Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 1 | 2 | Kami MaddocksOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT01699152 | Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 | 16 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 25, 2019 | clinicaltrials |
| NCT01638936 | BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01372540 | Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | completed | Phase 1 | 76 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2019 | clinicaltrials |
| NCT00850057 | Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | completed | Phase 1 | 16 | University of California, San DiegoOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT02811822 | A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma | completed | Phase 1 | 10 | GlycoMimetics IncorporatedINDUSTRY | 4 | Jul 10, 2019 | clinicaltrials |
| NCT02401048 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | completed | Phase 1 / Phase 2 | 61 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT01830816 | Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment | completed | Phase 1 | 41 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jun 10, 2019 | clinicaltrials |
| NCT00916058 | Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 57 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT00880815 | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | completed | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | completed | Phase 1 | 58 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | May 31, 2019 | clinicaltrials |
| NCT02426723 | Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients | completed | Phase 1 | 25 | JW PharmaceuticalINDUSTRY | 2 | May 17, 2019 | clinicaltrials |
| NCT00002787 | Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation | completed | Phase 1 | 22 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT00863174 | A Bioequivalence Study of SPARC_147709 in Patients With Multiple Myeloma | completed | Phase 1 | 24 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 0 | May 3, 2019 | clinicaltrials |
| NCT01246063 | Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01521611 | Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy | completed | Phase 1 / Phase 2 | 62 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00586924 | A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia | completed | Phase 1 | 49 | MedImmune LLCINDUSTRY | 2 | Apr 2, 2019 | clinicaltrials |
| NCT01383928 | Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 21, 2019 | clinicaltrials |
| NCT01556438 | Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma | completed | Phase 1 | 16 | Eli Lilly and CompanyINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT02497378 | A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Mar 7, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02745769 | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | completed | Phase 1 | 23 | Eli Lilly and CompanyINDUSTRY | 3 | Mar 5, 2019 | clinicaltrials |
| NCT01440582 | Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | completed | Phase 1 | 77 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT02549651 | MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) | completed | Phase 1 | 32 | MedImmune LLCINDUSTRY | 4 | Feb 27, 2019 | clinicaltrials |
| NCT00943319 | Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies | completed | Phase 1 / Phase 2 | 50 | University of ChicagoOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT01897012 | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 28, 2019 | clinicaltrials |
| NCT01634217 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02976857 | A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects(C-CAR011) | completed | Phase 1 | 15 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Jan 17, 2019 | clinicaltrials |
| NCT01549431 | Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple Myeloma | completed | Phase 1 | 32 | Emory UniversityOTHER | 1 | Jan 16, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Dec 16, 2019source: clinicaltrials